Mobile App to extend life expectancy of lung cancer patients

Image by Featureflash Photo Agency via ShutterStock
  • A new mobile app could help doctors provide better care to lung cancer patients
  • Moovcare enables doctor-patient communication even at a distance
  • The app is still at the prototype stage and will be out in the market in 2017

Helping doctors provide care to patients with advanced lung cancer, and perhaps extending life expectancy is possible through a smartphone, said a study presented in the United States on Monday.

An application named “Moovcare” enables doctors-patient communication even at a distance. The application facilitates lung cancer patients to submit weekly reports of their symptoms to their doctors via the app.

According to the report of Agence France-Presse published in ABS-CBN, the use of remote monitoring Moovcare app can quickly detect relapses or complications. Dr. Fabrice Denis, a cancer researcher in Le Mans, France said that this kind of approach can give the patients regular feedback in between visits.

Participants in the study who used the Moovcare app testified there was an improved quality of life and survived for an average of 19 months or seven months longer compared to patients receiving standard medical care.

One hundred thirty-three patients were randomly selected to test the app or to receive standard medical care following radiation treatment, chemotherapy, or surgery. After a year, the result was released which revealed that 75 percent of the patients using the app were still alive compared to 49 percent in the control group.

Gregory Masters, an expert in lung cancer, said that medical technologies like Moovcare app can make communication between doctor and patients simpler. He added the app will be great for doctors and even better for patients.

However, the smartphone app developed by Dr. Denis is still at its prototype stage. The study was funded by Sivan Innovation and the Cancer Institute of Western France and the results were presented during the annual American Society of Clinical Oncology (ASCO) conference in Chicago.

Moovcare is not available on the market yet, but the Israeli firm Sivan Innovation expects it to be out commercially in 2017. Its price is yet to be determined.

Based from an article posted in The Express Tribune, lung cancer is the most common cancer worldwide with 1.8 million diagnoses and 1.59 million deaths in 2012.

Loading…